Literature DB >> 9049963

The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT).

O Ringdén1, J Hermans, M Labopin, J Apperley, N C Gorin, A Gratwohl.   

Abstract

The purpose of the present study was to evaluate the relation between the grade of acute graft-versus-host disease (GVHD) and several outcome parameters. Special attention was given to leukaemia-free survival (LFS). The study included 2,122 patients with acute leukaemia in first remission and 780 patients with chronic myeloid leukaemia (CML) in the first chronic phase, who were receiving first transplants from HLA-identical donors. Transplant-related mortality (TRM) was the same in patients with or without grade I acute GVHD, but was increased in patients with grades II, III and IV acute GVHD. In patients with grades 0, I, II, III and IV acute GVHD, the five-year probability of TRM (+/-SE) overall was 20 +/- 1%, 19 +/- 2%, 30 +/- 2%, 61 +/- 4% and 90 +/- 3%, respectively. The incidence of relapse in patients with grades I-IV was lower than in patients without acute GVHD. The five-year relapse probability according to GVHD grade (0-IV), was 28 +/- 2%, 22 +/- 2%, 22 +/- 2%, 17 +/- 5% and 20 +/- 2%. The five-year LFS in all patients with leukaemia, according to grade of acute GVHD, was 57 +/- 2%, 63 +/- 2%, 55 +/- 3%, 32 +/- 4% and 8 +/- 3%. In multivariate analysis, adjustments for age, sex, diagnosis, interval from diagnosis to transplantation, T-cell depletion and year of transplantation were considered. Patients with grade I acute GVHD had the highest LFS (relative risk 0.84, p = 0.04 compared with those without acute GVHD).

Entities:  

Mesh:

Year:  1996        PMID: 9049963     DOI: 10.3109/10428199609045715

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  14 in total

1.  Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution.

Authors:  H Nahi; M Remberger; M Machaczka; J Ungerstedt; J Mattson; O Ringden; Katarina Le-Blanc; P Ljungman; H Hägglund
Journal:  Med Oncol       Date:  2012-01-11       Impact factor: 3.064

2.  Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings?

Authors:  O Ringdén; M Labopin; F Ciceri; A Velardi; A Bacigalupo; W Arcese; A Ghavamzadeh; R M Hamladji; C Schmid; A Nagler; M Mohty
Journal:  Leukemia       Date:  2015-08-21       Impact factor: 11.528

Review 3.  Chronic graft-versus-host disease: Pathogenesis and clinical management.

Authors:  José A Pérez-Simón; Ignacio Sánchez-Abarca; María Díez-Campelo; Dolores Caballero; Jesús San Miguel
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis.

Authors:  M Stern; L C de Wreede; R Brand; A van Biezen; P Dreger; M Mohty; T M de Witte; N Kröger; T Ruutu
Journal:  Leukemia       Date:  2014-04-30       Impact factor: 11.528

5.  Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease.

Authors:  Caitlin W Elgarten; Danielle E Arnold; Nancy J Bunin; Alix E Seif
Journal:  Pediatr Blood Cancer       Date:  2017-07-27       Impact factor: 3.167

Review 6.  Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.

Authors:  Shaheen Khan; David E Gerber
Journal:  Semin Cancer Biol       Date:  2019-07-19       Impact factor: 15.707

7.  General health, symptom occurrence, and self-efficacy in adult survivors after allogeneic hematopoietic stem cell transplantation: a cross-sectional comparison between hospital care and home care.

Authors:  Karin Bergkvist; Jeanette Winterling; Eva Johansson; Unn-Britt Johansson; Britt-Marie Svahn; Mats Remberger; Jonas Mattsson; Joacim Larsen
Journal:  Support Care Cancer       Date:  2014-10-17       Impact factor: 3.603

8.  The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.

Authors:  Olle Ringdén; Steven Z Pavletic; Claudio Anasetti; A John Barrett; Tao Wang; Dan Wang; Joseph H Antin; Paolo Di Bartolomeo; Brian J Bolwell; Christopher Bredeson; Mitchell S Cairo; Robert P Gale; Vikas Gupta; Theresa Hahn; Gregory A Hale; Jorg Halter; Madan Jagasia; Mark R Litzow; Franco Locatelli; David I Marks; Philip L McCarthy; Morton J Cowan; Effie W Petersdorf; James A Russell; Gary J Schiller; Harry Schouten; Stephen Spellman; Leo F Verdonck; John R Wingard; Mary M Horowitz; Mukta Arora
Journal:  Blood       Date:  2008-12-04       Impact factor: 22.113

Review 9.  Prospects for immunotherapy of malignant disease.

Authors:  E C Morris; G M Bendle; H J Stauss
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

10.  Haploidentical hematopoietic stem cell transplantation following myeloablative conditioning regimens in hematologic diseases with G-CSF-mobilized peripheral blood stem cells grafts without T cell depletion: a single center report of 38 cases.

Authors:  Rui-Nan Lu; Kou-Rong Miao; Run Zhang; Ming Hong; Ji Xu; Yu Zhu; Hua-Yuan Zhu; Xiao-Yan Qu; Shuai Wang; Li Wang; Lei Fan; Wen-Yi Shen; Hua Lu; Hong-Xia Qiu; Xiao-Yan Zhang; Li-Juan Chen; Wei Xu; Jian-Yong Li; Han-Xin Wu; Si-Xuan Qian
Journal:  Med Oncol       Date:  2014-07-08       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.